Avian Influenza A (H7N9) virus

Human infections with a new avian influenza A (H7N9) virus continue to be reported. Our team is working diligently to gather all relevant information related to the Avian Influenza (H7N9) virus. Below are the listings of the recommended protocols and the relevant products.

Recommended protocols

Products for Human Surveillance

SuperScript® III Platinum® One-Step qRT-PCR
Part of the Human Health response to this disease outbreak and are among the solutions recommended by the Centers for Disease Control and Prevention.
Product Packaging Sizes:

AgPath™ OneStep RT-PCR Master Mix *
Part of the Human Health response to this disease outbreak and are among the solutions recommended by several International Disease Control Centers.
Product Packaging Sizes:

TaqMan® Avian Influenza Virus (AIV-M) Reagents – SKU 4405543
Based on the design recommended by the US National Veterinary Service Laboratories for screening for Avian Influenza and is widely utilized around the world. This product contains reagents ONLY and should be combined with TaqMan® Avian Influenza Virus (AIV-M) and Xeno™ RNA Controls SKU 4405544.Product Insert Sheet for the ReagentsProduct Insert Sheet for the Controls

The CDC’s Influenza A/H7 (Eurasian Lineage) Real-Time RT-PCR Diagnostic Assay has received Emergency Use Authorization for detection in patient specimens of the novel influenza A (H7/N9) virus and not for the diagnosis of any other viruses or pathogens. The CDC A/H7 Assay has not been FDA cleared or approved, nor has FDA determined, as permitted under section 564(m) of the Act, that this test may be performed in settings with certificates of waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a. The CDC A/H7 Assay is only authorized for the duration of the declaration of emergency under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C § 360bbb-#(b)(1), unless the authorization is revoked sooner and the declaration of emergency will terminate when the HHS Secretary determines that the circumstances of a significant potential for a public health emergency have ceased to exist or when there is a change in the approval status of the CDC A/H7 Assay such that the authorization of emergency use is no longer needed, whichever occurs earlier.